Cullinan Therapeutics, Inc.
Status: Publicly traded
Last reviewed: October 2026
Direct answer
Cullinan Therapeutics, Inc. is publicly traded on NASDAQ under the ticker CGEM.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3...
Can you invest in Cullinan Therapeutics, Inc.?
Yes. Cullinan Therapeutics, Inc. is publicly traded on NASDAQ under the ticker CGEM.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Cullinan Therapeutics, Inc.
Detailed equity research is provided by MarketSnap.